HBM and AstraZeneca Deepen ADC/TCE Collaboration as AstraZeneca Exercises License Options
HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration...
HBM Holdings
Nona Biosciences Licenses HCAb Platform to Pfizer for Antibody Discovery
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a non‑exclusive licensing...
HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration
HBM Holdings Limited (HKG: 2142) and Evinova, an independent health‑tech arm of the AstraZeneca Group,...
HBM’s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co‑Develop In‑Vivo CAR‑T Platforms
HBM Holdings Limited (HKG: 2142) announced that its wholly‑owned subsidiary Nona Biosciences (Suzhou) Co., Ltd....
Nona Biosciences and Atossa Therapeutics Forge Partnership to Advance Breast Cancer Therapies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced the introduction of...
Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with...
Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...
Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement...
Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer
Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview...
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have...
Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration...